The Efficacy Observation of Polymyxin B in Multiple Drug-Resistant Gram-Negative Bacterial Infections in Critically Ill Children
Objective:The aim of this study was to assess the efficacy of polymyxin B in multiple drug-resistant Gram-negative bacterial infections in critically ill children and discuss the potential factors affecting the efficacy of polymyxin B.Methods:A total of 26 pediatric patients with multiple drug-resistant Gram-negative bacterial infections who were admitted to the intensive care unit between February 2020 and June 2022 were selected for this study.The study assigned the patients into two groups based on their clinical response:a group of 14 cases with response and a group of 12 cases without response.Various factors between the two groups were compared in the study,including gender,age,pediatric risk of mortality(PRISM)scores,coexisting diseases,pathogens,treatment duration,mechanical ventilation status,and concomitant use of other antimicrobial agents.Logistic regression was performed on variables with statistical significance to explore the factors affecting the efficacy of polymyxin B.Results:No statistically significant differences were found in gender,age,pediatric risk of mortality scores,coexisting diseases,pathogens,and concomitant use of other antimicrobial agents between the responsive and non-responsive groups(P>0.05).However,the duration of polymyxin B use was longer in the responsive group than in the non-responsive group(P=0.000),and a higher number of children in the non-responsive group required mechanical ventilation(P=0.034).Logistic regression analysis was conducted to identify potential factors affecting the clinical efficacy of polymyxin B in multiple drug-resistant Gram-negative bacterial infections in critically ill children.The analysis suggested that treatment duration(OR:2.606,95%CI:1.346～5.046,P=0.004)was a significant factor.Conclusion:Polymyxin B is effective in multiple drug-resistant Gram-negative bacterial infections in critically ill children.The duration of treatment is a potential factor that affects the clinical efficacy of polymyxin B.
万方数据
维普
